AZD2115 Multiple Ascending Dose Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate the safety and tolerability of AZD2115 following administration of multiple ascending doses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AZD5423 Multiple Ascending Dose Study

NCT01037504

Healthy

COMPLETED PHASE1

AZD8848 Single Ascending Dose Study

NCT01560234

Healthy

COMPLETED PHASE1

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects

NCT01818869

Safety, Tolerability, Healthy Subjects

COMPLETED PHASE1

AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers

NCT00829127

Healthy

WITHDRAWN PHASE1

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

NCT01636024

Safety Pharmacokinetics Pharmacodynamics of AZD7594

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Inhaled Doses of AZD2115 in Healthy Male Subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

AZD2115

Group Type EXPERIMENTAL

AZD2115

Intervention Type DRUG

Multiple dose, oral inhalation (nebuliser solution)

2

Placebo to AZD2115

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Multiple dose, oral inhalation (nebuliser solution)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD2115

Multiple dose, oral inhalation (nebuliser solution)

Intervention Type DRUG

Placebo

Multiple dose, oral inhalation (nebuliser solution)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male subjects aged 18 to 45 years with suitable veins for cannulation or repeated venepuncture
* Male subjects should be willing to use barrier contraception ie, condoms and spermicide, from the day of first administration of the AZD2115 until 3 months after administration and must not donate sperm for 3 months after follow-up
* Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg

Exclusion Criteria

* Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:

* Systolic BP \>140 mmHg
* Diastolic BP \>90 mmHg
* Heart rate \<40 or \>85 bpm
* Prolonged QTcF \>450 ms or shortened QTcF \<340 ms or family history of long QT syndrome
* Serum potassium concentration of \< 3.80 mmol/L on admission (Day -1)
* History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with the same class to AZD2115 or to excipients
* History or presence of gastrointestinal, pulmonary, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes